Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast versus vitamin E for non-alcoholic steatohepatitis
PACTR202410748072574Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of roflumilast and vitamin e in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Tanta University. Primary endpoint: Change in liver stiffness measurement. Started Jan 2022; status: recruiting.
02
Drugs
roflumilastvitamin e
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on PACTR202410748072574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410748072574.